Kothari Ferment. (507474)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth is positive at 4.65%, and latest quarter sales of ₹32 Cr show some revenue traction.
• ROCE of 5.46% suggests operating capital is not entirely value-destructive.
• Book value of ₹37.50 per share provides a tangible asset base, even though price is 1.89x book.
• Stock has risen from ₹30.20 low to ₹70.95, indicating market optimism about a possible recovery.
• Small market cap of ₹109 Cr leaves room for a focused niche operator to improve returns.

Concerns

• Negative ROE of -6.39% and profit growth of -192.68% mean the business is currently loss-making; P/E is meaningless.
• Piotroski F-score of 4/9 points to weak financial health and poor fundamental quality.
• No dividend means minority shareholders depend entirely on capital gains.
• Debt/equity and promoter holding are not disclosed, leaving critical balance-sheet and governance risks unknown.

AI Analysis

Let me look at Kothari Ferment as if buying the entire business. At ₹70.95, the market cap is ₹109 Cr against book value of ₹37.50 per share. That means I am paying 1.89 times book for assets that currently earn a negative return on equity of -6.39%. Graham would insist on a margin of safety; here I see very little. The P/E is meaningless because profits have collapsed—profit growth is -192.68%—and the latest quarter's net profit is roughly zero. Sales growth of 4.65% is modest, but a business with no clear pricing power and a commodity-like food processing operation is not a wonderful compounder. ROCE at 5.46% is below what a simple bond might offer, and with debt/equity not disclosed, I cannot judge balance-sheet risk. No dividend means I must rely entirely on price appreciation, which is speculative. The 52-week range shows the stock has more than doubled from ₹30.20 to ₹70.95, and it now sits at the high. The market may be anticipating a turnaround, but the Piotroski F-score of 4 out of 9 tells me financial health is weak. Promoter holding is also not available, so I cannot see whether insiders have skin in the game. This is a small-cap food business with a narrow potential moat, if any. I need evidence of durable earnings, better returns on capital, and honest disclosure before I part with my money. At this price, the risk-reward is unfavorable. I would rather wait for a margin of safety, or a demonstrated improvement in profitability that justifies the premium.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer